Xilio Therapeutics, Inc.’s Post

View organization page for Xilio Therapeutics, Inc., graphic

8,187 followers

Alongside news of our Q2 2024 earnings and pipeline progress yesterday, we announced the promotion of Christopher Frankenfield to chief financial officer while continuing to serve in his role as chief operating officer. Chris has been integral to guiding Xilio's strategic growth since he joined us in 2021, and we are confident in his continued leadership as we advance our robust pipeline of tumor-activated immunotherapies to treat cancer. https://lnkd.in/eDzrgytg

To view or add a comment, sign in

Explore topics